Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONTO-Compare
2017-003399-30Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing LY900014 + basal insulin with Fiasp + basal insulin (2 arms). Primary endpoint: Primary: Change from baseline to Week 20 in HbA1c. Started Oct 2018; status: terminated.
02
Drugs
insulin lisprohuman insulin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2017-003399-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003399-30.